Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to Rp2,100, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 18x in the Chemicals industry in Indonesia. Total returns to shareholders of 2.0% over the past three years. Recent Insider Transactions • Jun 06
Director of Polymer Sales & Director recently bought Rp8.2b worth of stock On the 3rd of June, Raymond Budhin bought around 5m shares on-market at roughly Rp1,798 per share. This transaction amounted to 90% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Rp23b more in shares than they have sold in the last 12 months. Major Estimate Revision • Jun 03
Consensus revenue estimates increase by 73% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$6.29m to US$10.9m. Now expected to report a profit of US$0.0069 instead of losses of -US$0.0004 per share. Chemicals industry in Indonesia expected to see average net income growth of 0.2% next year. Consensus price target up from Rp1,090 to Rp1,750. Share price fell 15% to Rp1,615 over the past week. Valuation Update With 7 Day Price Move • May 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to Rp1,900, the stock trades at a trailing P/E ratio of 7.3x. Average forward P/E is 12x in the Chemicals industry in Indonesia. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • May 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to Rp5,050, the stock trades at a trailing P/E ratio of 19.8x. Average forward P/E is 13x in the Chemicals industry in Indonesia. Total returns to shareholders of 128% over the past three years. New Risk • May 01
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 9.1% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (9.1% operating cash flow to total debt). Earnings are forecast to decline by an average of 150% per year for the foreseeable future. High level of non-cash earnings (29% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). New Risk • Apr 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 138% per year for the foreseeable future. High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Announcement • Apr 07
PT Chandra Asri Pacific Tbk, Annual General Meeting, May 13, 2026 PT Chandra Asri Pacific Tbk, Annual General Meeting, May 13, 2026. Valuation Update With 7 Day Price Move • Apr 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to Rp4,170, the stock trades at a trailing P/E ratio of 19.5x. Average forward P/E is 16x in the Chemicals industry in Indonesia. Total returns to shareholders of 83% over the past three years. Reported Earnings • Mar 28
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: US$0.015 (up from US$0.001 loss in FY 2024). Revenue: US$7.02b (up 293% from FY 2024). Net income: US$1.09b (up US$1.16b from FY 2024). Profit margin: 16% (up from net loss in FY 2024). Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is expected to decline by 1.8% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Indonesia are expected to grow by 7.4%. Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to Rp5,975, the stock trades at a trailing P/E ratio of 23.8x. Average forward P/E is 21x in the Chemicals industry in Indonesia. Total returns to shareholders of 168% over the past three years. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to Rp7,250, the stock trades at a trailing P/E ratio of 28.9x. Average forward P/E is 20x in the Chemicals industry in Indonesia. Total returns to shareholders of 212% over the past three years. Announcement • Feb 04
PT Chandra Asri Pacific Tbk (IDX:TPIA) announces an Equity Buyback for 250,000,000 shares, representing 0.29% for IDR 2,000,000 million. PT Chandra Asri Pacific Tbk (IDX:TPIA) announces a share repurchase program. Under the program, the company will repurchase up to 250,000,000 shares for 0.29% of its issued share capital, for a total of IDR 2,000,000 million. The shares will be purchased at maximum price of IDR 10,000 per share. The purpose of program is to increase value for shareholders, improve shares performance in accordance with the Company's fundamental conditions, maintain the Company’s shares price stabilization and maintain public trust. The repurchases will be funded from company's internal cash. The program will be valid till May 3, 2026. Recent Insider Transactions • Dec 17
Director of Polymer Sales & Director recently bought Rp1.4b worth of stock On the 12th of December, Raymond Budhin bought around 200k shares on-market at roughly Rp7,100 per share. This transaction amounted to 6.5% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp2.1b. Despite this recent purchase, insiders have collectively sold Rp149b more in shares than they bought in the last 12 months. Recent Insider Transactions • Dec 13
Director of Polymer Sales & Director recently bought Rp1.5b worth of stock On the 5th of December, Raymond Budhin bought around 200k shares on-market at roughly Rp7,656 per share. This transaction amounted to 7.1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp2.1b. Despite this recent purchase, insiders have collectively sold Rp152b more in shares than they bought in the last 12 months. Major Estimate Revision • Dec 04
Consensus EPS estimates increase from loss to US$0.00 profit The consensus outlook for fiscal year 2025 has been updated. 2025 forecast for profit of -US$0.002 instead of a loss of US$0.00 per share previously. Revenue forecast unchanged at US$6.52m. Chemicals industry in Indonesia expected to see average net income growth of 30% next year. Consensus price target of Rp4,713 unchanged from last update. Share price rose 3.4% to Rp7,625 over the past week. Recent Insider Transactions • Nov 21
Director of Finance & Director recently bought Rp1.0b worth of stock On the 18th of November, Kah Khor bought around 136k shares on-market at roughly Rp7,450 per share. This transaction amounted to 46% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth Rp1.6b. This was Kah's only on-market trade for the last 12 months. Announcement • Nov 17
PT Chandra Asri Pacific Tbk announced that it has received $750 million in funding PT Chandra Asri Pacific Tbk announced that it has received $750 Million in round of funding on November 16, 2025. The transaction included the participation from new lender KKR & Co. Inc. The company issued non-convertible debt in the transaction. Upcoming Dividend • Nov 04
Upcoming dividend of Rp3.84 per share Eligible shareholders must have bought the stock before 11 November 2025. Payment date: 28 November 2025. Payout ratio is a comfortable 2.4% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indonesian dividend payers (5.3%). Lower than average of industry peers (0.3%). Reported Earnings • Nov 01
Third quarter 2025 earnings released: EPS: US$0 (vs US$0 in 3Q 2024) Third quarter 2025 results: EPS: US$0 (in line with 3Q 2024). Revenue: US$2.45b (up US$2.08b from 3Q 2024). Net income: US$24.7m (up US$37.1m from 3Q 2024). Profit margin: 1.0% (up from net loss in 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, earnings per share has increased by 132% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Price Target Changed • Oct 24
Price target increased by 167% to Rp4,713 Up from Rp1,763, the current price target is an average from 3 analysts. New target price is 35% below last closing price of Rp7,275. Stock is down 20% over the past year. The company is forecast to post a net loss per share of US$0.002 next year compared to a net loss per share of US$0.00097 last year. Announcement • Jul 24
PT Chandra Asri Pacific Tbk (IDX:TPIA) acquired 11.9% stake in Hiap Seng Industries Limited (SGX:1L2). PT Chandra Asri Pacific Tbk (IDX:TPIA) acquired 11.9% stake in Hiap Seng Industries Limited (SGX:1L2) on July 23, 2025.
PT Chandra Asri Pacific Tbk (IDX:TPIA) completed the acquisition of 11.9% stake in Hiap Seng Industries Limited (SGX:1L2) on July 23, 2025. Announcement • May 06
PT Chandra Asri Pacific Tbk, Annual General Meeting, Jun 11, 2025 PT Chandra Asri Pacific Tbk, Annual General Meeting, Jun 11, 2025. Location: jakarta Indonesia Reported Earnings • Nov 04
Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023) Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$365.1m (down 38% from 3Q 2023). Net loss: US$12.4m (loss narrowed 40% from 3Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 134 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Aug 31
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.50m to US$2.23m. Forecast loss of -US$0.0018, down from profit of US$0.0005 per share profit previously. Chemicals industry in Indonesia expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at Rp1,763. Share price rose 7.0% to Rp9,975 over the past week. Recent Insider Transactions • Aug 27
Director & Polymer Sales Director recently bought Rp192m worth of stock On the 22nd of August, Raymond Budhin bought around 20k shares on-market at roughly Rp9,600 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp276m. Insiders have collectively bought Rp2.4b more in shares than they have sold in the last 12 months. Reported Earnings • Aug 02
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: US$394.6m (down 31% from 2Q 2023). Net loss: US$14.3m (loss widened 57% from 2Q 2023). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 152 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jul 11
Director & Polymer Sales Director recently bought Rp276m worth of stock On the 8th of July, Raymond Budhin bought around 30k shares on-market at roughly Rp9,183 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp468m. Insiders have collectively bought Rp2.2b more in shares than they have sold in the last 12 months. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023) First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$471.9m (down 6.1% from 1Q 2023). Net loss: US$33.1m (down 487% from profit in 1Q 2023). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 140 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 01
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: US$0 (improved from US$0.002 loss in FY 2022). Revenue: US$2.16b (down 9.4% from FY 2022). Net loss: US$33.6m (loss narrowed 78% from FY 2022). Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 116 percentage points per year, which is a significant difference in performance. New Risk • Feb 23
New major risk - Revenue and earnings growth Earnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 42% per year over the past 5 years. New Risk • Dec 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 05
Third quarter 2023 earnings released: EPS: US$0 (vs US$0.001 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0 (improved from US$0.001 loss in 3Q 2022). Revenue: US$588.3m (down 3.8% from 3Q 2022). Net loss: US$20.8m (loss narrowed 56% from 3Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Sep 29
President Director recently bought Rp1.1b worth of stock On the 25th of September, Erwin Ciputra bought around 400k shares on-market at roughly Rp2,723 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Erwin has been a buyer over the last 12 months, purchasing a net total of Rp2.1b worth in shares. Recent Insider Transactions • Sep 23
President Director recently bought Rp993m worth of stock On the 18th of September, Erwin Ciputra bought around 462k shares on-market at roughly Rp2,149 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Erwin's only on-market trade for the last 12 months. Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: US$0 (vs US$0.001 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0 (improved from US$0.001 loss in 2Q 2022). Revenue: US$572.0m (down 13% from 2Q 2022). Net loss: US$9.16m (loss narrowed 83% from 2Q 2022). Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Reported Earnings • Jun 21
First quarter 2023 earnings released: EPS: US$0 (vs US$0 in 1Q 2022) First quarter 2023 results: EPS: US$0 (in line with 1Q 2022). Revenue: US$502.3m (down 26% from 1Q 2022). Net income: US$8.57m (up US$19.8m from 1Q 2022). Profit margin: 1.7% (up from net loss in 1Q 2022). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Price Target Changed • Mar 22
Price target decreased by 8.1% to Rp2,175 Down from Rp2,366, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of Rp2,250. Stock is down 6.0% over the past year. The company posted earnings per share of US$0.0019 last year. Reported Earnings • Nov 06
Second quarter 2022 earnings released: US$0.001 loss per share (vs US$0.001 profit in 2Q 2021) Second quarter 2022 results: US$0.001 loss per share (down from US$0.001 profit in 2Q 2021). Revenue: US$658.8m (flat on 2Q 2021). Net loss: US$53.4m (down 167% from profit in 2Q 2021). Revenue is expected to fall by 4.2% p.a. on average during the next 3 years compared to a 1.6% decline forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Price Target Changed • Sep 24
Price target increased to Rp3,753 Up from Rp2,366, the current price target is an average from 3 analysts. New target price is 46% above last closing price of Rp2,570. Stock is up 43% over the past year. The company posted earnings per share of US$0.0019 last year. Price Target Changed • Jul 12
Price target increased to Rp10,150 Up from Rp9,063, the current price target is an average from 2 analysts. New target price is 16% above last closing price of Rp8,725. Stock is down 12% over the past year. The company posted earnings per share of US$0.0075 last year. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.008 (up from US$0.003 in FY 2020). Revenue: US$2.58b (up 43% from FY 2020). Net income: US$152.1m (up 196% from FY 2020). Profit margin: 5.9% (up from 2.8% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 3.0%, compared to a 25% growth forecast for the industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year. Price Target Changed • Mar 10
Price target decreased to Rp8,427 Down from Rp9,101, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of Rp8,525. Stock is down 14% over the past year. The company posted earnings per share of US$0.0029 last year. Buying Opportunity • Feb 25
Now 20% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be US$11,222, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% per annum over the last 3 years. Earnings per share has been flat over the last 3 years. Valuation Update With 7 Day Price Move • Feb 08
Investor sentiment improved over the past week After last week's 16% share price gain to Rp10,200, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 14x in the Chemicals industry in Asia. Total returns to shareholders of 111% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Rp11,183 per share. Price Target Changed • Dec 07
Price target decreased to Rp8,721 Down from Rp9,650, the current price target is an average from 4 analysts. New target price is 27% above last closing price of Rp6,850. Stock is down 30% over the past year. The company is forecast to post earnings per share of US$0.019 for next year compared to US$0.0029 last year. Valuation Update With 7 Day Price Move • Sep 09
Investor sentiment deteriorated over the past week After last week's 19% share price decline to Rp6,975, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Chemicals industry in Asia. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Rp11,436 per share. Major Estimate Revision • Aug 06
Consensus EPS estimates increase to US$0.025 The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$2.49m to US$2.59m. EPS estimate increased from US$0.012 to US$0.025 per share. Net income forecast to grow 181% next year vs 30% growth forecast for Chemicals industry in Indonesia. Consensus price target up from Rp8,700 to Rp9,675. Share price was steady at Rp9,350 over the past week. Price Target Changed • Aug 06
Price target increased to Rp9,675 Up from Rp8,700, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of Rp9,350. Stock is up 27% over the past year. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment improved over the past week After last week's 19% share price gain to US$9,575, the stock trades at a forward P/E ratio of 60x. Average forward P/E is 16x in the Chemicals industry in Asia. Total returns to shareholders of 86% over the past three years. Price Target Changed • Mar 09
Price target raised to Rp8,750 Up from Rp8,110, the current price target is an average from 4 analysts. The new target price is 8.4% below the current share price of Rp9,550. As of last close, the stock is up 24% over the past year. Reported Earnings • Mar 05
Full year 2020 earnings released: EPS US$0.003 (vs US$0.001 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: US$1.81b (down 4.0% from FY 2019). Net income: US$51.4m (up 124% from FY 2019). Profit margin: 2.8% (up from 1.2% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 93% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Mar 05
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 126%. Over the next year, revenue is forecast to grow 13%, compared to a 14,195% growth forecast for the Chemicals industry in Indonesia. Is New 90 Day High Low • Feb 01
New 90-day high: Rp10,625 The company is up 34% from its price of Rp7,950 on 04 November 2020. The Indonesian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp771 per share. Is New 90 Day High Low • Jan 09
New 90-day high: Rp10,050 The company is up 29% from its price of Rp7,775 on 09 October 2020. The Indonesian market is up 21% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Chemicals industry, which is also up 29% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp765 per share. Is New 90 Day High Low • Dec 08
New 90-day high: Rp9,775 The company is up 43% from its price of Rp6,825 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 37% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp621 per share. Is New 90 Day High Low • Nov 16
New 90-day high: Rp8,450 The company is up 14% from its price of Rp7,400 on 18 August 2020. The Indonesian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp644 per share. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total losses of US$28.3m, with earnings decreasing by US$71.3m from the prior year. Total revenue was US$1.76b over the last 12 months, down 11% from the prior year. Is New 90 Day High Low • Oct 24
New 90-day high: Rp7,900 The company is up 6.0% from its price of Rp7,450 on 24 July 2020. The Indonesian market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp435 per share. Is New 90 Day High Low • Oct 03
New 90-day high: Rp7,550 The company is up 10.0% from its price of Rp6,875 on 03 July 2020. The Indonesian market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp434 per share. Announcement • Sep 22
PT Chandra Asri Petrochemical Unveils Trilene® HI50TN PT Chandra Asri Petrochemical unveils Trilene® HI50TN, Thin Wall Injection Molded (TWIM) polypropylene (PP) food containers to revolutionize the use of TWIM container as preferred choice for Food Packaging. The initiative is considered a breakthrough in the implementation of reusable packaging, due to the use of more hygienic and environmentally friendly materials. Trilene® HI50TN is also approved for use by the Food and Drug Administration (FDA) and compliant with halal standards, ensuring safety and quality. The light-weight thin-walled PP food containers were introduced by PT Chandra Asri Petrochemical to distribute sacrificial meats during Eid Al-Adha in July. Trilene® HI50TN is developed with Milliken's Hyperform® (HPN™) Performance Additives for use in TWIM PP food containers. Through enhanced aesthetics, Milliken's HPN allows consumers to clearly see the freshness of packaged food, building consumer confidence by ensuring excellent food quality. It also gives dimensional stability for leak-proof transport; as well as providing a higher heat resistance for safe microwave use. Hyperform HPN™ Performance Additives help to speed up the TWIM PP container production process at molders. Being UL certified, Hyperform HPN also provides a significant reduction in energy consumption and carbon footprint. Overall, Hyperform HPN™ provides a sustainable solution to the food packaging industry and an environmental-friendly alternative for consumers. 
